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Abstract
Background—The recently developed composite autonomic symptom score-31 
(COMPASS-31) is a questionnaire for assessing symptoms of dysautonomia. It was distilled from 
the well established autonomic symptom profile questionnaire. COMPASS-31 has not yet been 
externally validated. To do so, we assessed its psychometric properties and its convergent validity 
in patients with or without objective diagnosis of small fiber polyneuropathy (SFPN).
Methods—The internal validity and reliability of COMPASS-31 were assessed in participants 
with or without SFPN spanning the full autonomic symptoms severity. Convergent validity was 
assessed by comparing results of the COMPASS-31 and the gold standard autonomic function 
testing (AFT) which measures cardiovagal, adrenergic, and sudomotor functions. Additionally, 
relationships between COMPASS-31 and the Short Form McGill pain questionnaire, Short Form 
Health Survey and a 0-10 numeric pain scale were assessed. COMPASS-31 and all other 
questionnaires results were compared between patients with or without evidence of SFPN, 
objectively confirmed by distal-leg PGP9.5-immunolabeled skin biopsy.
Results—Among 66 participants (28 SFPN+, 38 SFPN-), COMPASS-31 total scores had 
excellent internal validity (Cronbach's α =0.919), test-retest reliability (rs=0.886; p<0.001), and 
good convergent validity (rs=0.474; p<0.001). COMPASS-31 scores differed between subjects 
with or without SFPN (Z=−3.296, p<0.001), and demonstrated fair diagnostic accuracy. Area 
under the receiver operating characteristic curve was 0.749 (P =0.01, 95% confidence interval 
0.627-0.871).
Conclusions—COMPASS-31 has good psychometric properties in the population of patients 
being evaluated for SFPN and thus it might be useful as an initial screening tool for the more 
expensive SFPN objective tests.
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Introduction
Assessing functioning of the autonomic nervous system is important in evaluation for 
common neurological disorders, including polyneuropathy and Parkinson's disease. 
Dysautonomia can cause multiple symptoms, including low blood pressure when standing 
(orthostatic hypotension), tachycardia, upper and lower gastrointestinal complaints, pupil 
and sweating abnormalities, and bladder and sexual dysfunction [1].
Objective diagnosis and quantification of dysautonomia is currently best accomplished (the 
“gold-standard”) by conducting a set of autonomic function tests (AFT), developed and 
refined primarily at Mayo Clinic, long the epicenter of this field. AFT includes measuring 
heart-rate variability in response to deep breathing and the valsalva maneuver, 
hemodynamic responses to 80° head-up tilt test, and 4-site acetylcholine-evoked quantitative 
sweat production [2]. AFT results are quantified using the composite autonomic severity 
score scale (CASS), that includes sub-scores for cardiovagal, adrenergic and sudomotor 
functions adding up to a 0 to 10 total scale score [2].
AFT requires expensive, non-portable equipment, operator training and patient preparations. 
It is available only at selected university centers, so symptom-based questionnaires are 
important surrogate. In 1999, Prof. Phillip Low and colleagues at Mayo Clinic developed the 
169-item autonomic symptom profile (ASP) questionnaire [3]. To improve clinical utility, 
85 questions from ASP were carefully selected to produce the composite autonomic 
symptom score (COMPASS). Although improved, COMPASS also was not widely adopted; 
it is time-consuming for patients and has a complex scoring system that requires training. To 
further increase applicability, Singer and Mayo Clinic colleagues further refined COMPASS 
to a 31-item, easily scored, questionnaire named COMPASS-31 (4) (available in 
supplementary material S1, online only). COMPASS-31 quantifies 6 domains: Orthostatic 
intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor. The 6 
subscales sum to a total COMPASS-31 score of 0 to 100 (scoring directions are available in 
supplementary material S2, online only). We are unaware of previous validations of 
COMPASS-31.
Small-fiber polyneuropathy (SFPN) is a polyneuropathy that exclusively or preferentially 
affects the small unmyelinated or thinly myelinated peripheral axons that serve nociception 
and autonomic function [5]. Dysfunction of small fibers causes autonomic and sensory 
abnormalities and SFPN patients typically report mixed of sensory and autonomic 
symptoms. Sensory symptoms can include reduced sensation, pain and/or itch. Autonomic 
symptoms include increased or decreased sweating, perfusion manifest as changed skin 
color or temperature, sexual dysfunction, orthostatic hypotension and gastrointestinal 
dysmotility [5]. SFPN is challenging to diagnose since the motor and reflex examinations 
remain normal and standard nerve-conduction and electromyography testing are insensitive. 
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Neurodiagnostic skin biopsy from the distal leg is the only objective diagnostic test for 
SFPN recommended by the American Academy of Neurology and the European Federation 
of Neurological Societies [6,7].
SFPN is a common cause of dysautonomia; it is frequently undiagnosed and disabling 
illness. Autonomic symptoms are characteristic of small-fiber mediated chronic pain 
syndromes, since the term “small fiber” encompasses both the sympathetic and nociceptive 
axons within peripheral nerves. Thus COMPASS-31 might serve as a screening tool for 
SFPN. We therefore assessed its internal validity, reliability and construct validity plus its 
ability to discriminate between participants diagnosed with, or without SFPN as confirmed 
by BIOPSIES .
Methods
Study Design and Subjects
All procedures and protocols had been approved by the hospital's institutional review board. 
Inclusion criteria comprised age at least 16 years and having completed AFT and biopsy 
within the last 12 months or being willing to undergo them. Both sexes and all races were 
eligible for inclusion. Exclusion criteria comprised inability to give informed consent, and 
any contraindication to AFT or biopsy. A sample size of at least 50 is recommended for 
validation studies [8], so we planned to recruit 60 subjects.
Participants were recruited from among patients and research subjects of the peripheral-
nerve group at Massachusetts General Hospital between June 2013 and April 2014. No 
specific condition or diagnosis was required for inclusion and all eligible participants were 
invited to participate by telephone, email, or in person. Participants were paid $10 for 
completing questionnaires on paper or via the internet and $50 for undergoing AFT or skin 
biopsy. Data were managed using Harvard Medical School's secure data capture (REDCap) 
platform [9], and accuracy of data entry was verified.
Primary Outcome
The composite autonomic symptom score (COMPASS 31)—COMPASS-31 was 
completed twice at two week intervals and scored as recommended [4]. COMPASS-31 total 
score range between 0 to 100, with high values representing severe symptoms. The first 
COMPASS-31 score was used in all analyses and the second COMPASS-31score was used 
only for test re-test reliability assessment.
Comparators
Autonomic Functioning Test—AFT was performed using standard clinical diagnostic 
methods and equipment (WR Medical Electronics, Stillwater, MN) as previously published 
[10,11]. Subjects were directed to not wear compressive clothing and not to smoke, eat, or 
consume alcohol or caffeine for 4 hours preceding testing. Their medications were reviewed 
and potentially interfering medications were held for 24-48 hours before testing. We 
measured heart-rate variability to deep breathing (6/minute while supine) and Valsalva 
maneuver, hemodynamic responses to 80° head-up tilt for 10 minutes, and acetylcholine 
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evoked sweat production. AFT total and sub-scores, with high values representing severe 
symptoms, were quantified using the standard, validated CASS [2]. This a validated 10-
point scale of autonomic function that includes three subscales (adrenergic 4 points; 
sudomotor and cardiovagal 3 points each). There are different scales for the sexes and 
different age groups. Scores of 7-10 are interpreted as indicating severe autonomic failure; 
score ≤3 indicate mild dysfunction and intermediate scores indicated moderate autonomic 
symptoms.
Numeric pain scale (NPS)—Subjects scored their average pain in the past 24 hours on a 
0-10 numeric pain scale (NPS), where 0 represented “no pain” and 100 represented the 
“worst pain one can imagine” [12].
The short-form McGill pain questionnaire (SF-MPQ-2)—This recommended 
secondary outcome pain measure [12;13] was completed by all subjects. Total scores and 4 
subscores (continuous pain, intermittent pain, neuropathic pain and affective descriptors) 
were calculated. SF-MPQ-2 score range between 0-10, with high values representing severe 
symptoms.
Short Form Health Survey (SF-36)—This recommended secondary outcome pain 
measure [12], was completed by all subjects and total scores plus physical- and mental-
health sub-scores were calculated [14]. SF-36 scores range between 0-100, with low values 
representing low health-related quality of life.
Small fiber polyneuropathy (SFPN) diagnosis by neurodiagnostic skin biopsy
All biopsies were removed from the standard site on the distal leg 10 cm above the lateral 
malleolus using local anesthesia, as previously published [11]. PGP9.5-immunolabeled 
epidermal neurites were measured in a blinded manner by experienced personnel in a Joint-
Commission accredited clinical diagnostic laboratory using best recommended practices and 
interpretation. The standard clinical diagnostic criteria for SFPN diagnosis, epidermal nerve 
fiber (ENF) density <5th centile of predicted laboratory norms were applied to categorize 
participants as having or not having SFPN [6,7]. Our laboratory's biopsy norms used for 
interpretation come from a series of 351 screened healthy subjects, 175 males and 176 
females, aged 8 through 92 years (mean 40.1 ± 18 years) (See abstract- Klein, MM, et al., 
Annals of Neurology 76[suppl 18], S69. 2014).
Data acquisition and analysis
Analyses were conducted using the SPSS for Windows version 19 statistical package (SPSS, 
Inc., Chicago, IL). Data distributions were assessed by the Shapiro-Wilk test and all 
variables were found to be not normally distributed (p<0.05), therefore non-parametric 
analyses were used and central tendencies were reported accordingly. COMPASS-31 
internal validity was assessed by Cronbach's α. Correlations were assessed by Spearman's 
correlations. Participants were dichotomized into two groups: ‘participants with SFPN’ (skin 
biopsy percentile results below the 5th centile) and ‘participants without SFPN’ (those with 
neurites densities above the 5th centile). Differences in all dependent variables between 
participants with and without SFPN diagnosis were assessed by using the Mann-Whitney U 
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test. Receiver operating characteristic (ROC) analysis was conducted with SFPN diagnosis 
as the state variable and COMPASS-31 as the test variable. Bonferroni corrections for 
multiple comparisons were independently applied.
Results
Participants
Sixty-six participants (46 females) met inclusion criteria and completed the first set of 
questionnaires. Their mean age was 42.2 ± 13.1 years, range 16 to 69. Forty-eight of 66 
participants (72.8%) reported somatosensory symptoms and 59/66 (89.4%) reported 
autonomic symptoms. Two weeks later, 58 completed the second COMPASS-31 for the test/
retest reliability assessment. Table 1 presents the COMPASS-31 scores.
Reliability of COMPASS-31
There was excellent test-retest reliability (rs=0.886, p<0.001) and internal validity, with 
Cronbach's α of 0.919 for the entire questionnaire. The domains for orthostatic intolerance, 
vasomotor, gastrointestinal and pupillomotor function had excellent to good internal 
validities (Cronbach's α 0.869-0.910). The bladder domain had low internal validity (0.598) 
and the secretomotor domain demonstrated unacceptable internal validity (0.246). Deleting 
question 8 (sweat related item) improved the validity of the secretomotor domain to “good” 
(0.731), and the Cronbach's α of the total score to 0.942.
Validity of COMPASS-31
Subjects’ AFT results as quantified by the CASS are presented in Table 2. Twenty-seven 
percent of subjects scored 0, meaning they had no objective evidence of dysautonomia. 
Forty-three percent had mild (CASS score = 1-3), 24% had moderate (total CASS score = 
4-6), and 6% had severe dysautonomia (CASS=7). This cohort thus effectively spanned the 
full range of symptom severity.
Table 3 demonstrates correlations between COMPASS-31 total and sub scores and the AFT. 
Among all AFT domains, the sudomotor had the strongest relations with COMPASS-31 
total and subscales scores.
Table 4 summarizes relationships between COMPASS-31 and the SF-MPQ-2, the SF-36, 
and participant's average pain scores in the past 24 hours. COMPASS-31 (both the total 
score and subscales) were strongly correlated with them all.
Comparing COMPASS-31 results between participants with or without SFPN
For both groups together, the mean ENF density was 173± 120 neurites per mm2 skin 
surface area (range 0-615). The mean centile was 21.3%±28.3, ranged 0%-95.68%. Twenty 
eight (42.4%) participants had skin biopsy diagnostic of SFPN and 38 (57.6%) were non 
diagnostic (see Table 5). Ten participants were identified as borderline SFPN, with neurites 
count between the 5th to the 15th centile. Given their low abundance they were tagged as 
without SFPN.
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The diagnostic potential of COMPASS-31 for SFPN was evaluated by ROC analysis (figure 
1). COMPASS-31 had fair accuracy with area under the curve = 0.749 (P=0.01; 95% 
confidence interval 0.627-0.871). The optimal cutoff for specificity based on minimal 
distance from the top-left corner of the ROC curve, is 30, with sensitivity of 0.741 and 
specificity of 0.730. To optimize screening performance (based on the curve coordinates), a 
cutoff of 10 in the total COMPASS-31 score had sensitivity of 0.926 and specificity of 0.378 
for identifying SFPN skin-biopsy confirmed as defined by the biopsy results.
Figure 1 to be located near here
Discussion
The current study assessed the psychometric properties of COMPASS 31 and validated it in 
a cohort of patients and research subjects with a wide range of autonomic symptoms. The 
results reveal excellent internal validity and test-retest reliability for COMPASS-31, with a 
medium to strong convergent validity as compared with AFT, the “gold standard” for 
objective autonomic evaluation [15]. In addition, COMPASS-31 total scores significantly 
distinguished participants with from without SFPN, suggesting potential diagnostic utility in 
this population.
COMPASS 31 was published in December 2012 by Sletten et al. [4]. Their study of 405 
healthy control subjects found internal consistency comparable to ours, with good to-
excellent Cronbach α for the orthostatic, vasomotor, gastrointestinal and pupillomotor 
domains, but lower values for secretomotor and bladder domains. They did not evaluated 
how Cronbach α could be improved by item exclusion, but our analysis finds that removing 
question 8 (sweat changes in the past 5 years) improves internal consistency for both this 
domain and the total COMPASS-31 score, so we recommend consideration of this 
modification for other populations. The current study was the first to assess COMPASS-31 
test-retest reliability which was excellent.
While good validity was demonstrated as compared with the total AFT score, the AFT 
sudomotor domain demonstrated the strongest correlation with the total COMPASS-31 
score. This may relate to the sudomotor test properties and its scoring. Unlike the other AFT 
tests, sweat production is measured at four sites. A score calculated out of multiple body 
sites is likely to better characterize dysautonomia severity, and thus its stronger correlation 
with the COMPASS-31 is not unexpected. Interestingly, the performance of COMPASS-31 
improves when the sweating item (question 8) is deleted, but the sudomotor domain of the 
AFT correlated best with the results of COMPASS-31. A likely explanation for this seeming 
discrepancy is that most patients remain unaware if they develop hypohydrosis on their 
limbs, but interpret the normal compensatory truncal hyperhydrosis as the abnormality.
Strengths of our study include the use of multiple comparators. Not only we compared the 
COMPASS-31 results with the AFT, we also assessed its relations with other pain related 
outcomes. The strong correlations between COMPASS-31 (which does not include pain-
related items) and questionnaires assessing pain and health related quality of life support use 
of COMPASS-31 in SFPN evaluation in both research and clinical settings. Further supports 
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for the latter claim are the differences observed between participants with or without skin 
biopsy diagnostic of SFPN in all studied measures. Another strength is that as far as we 
know, The SFMPQ-2, developed in 2009 [13], has not yet been validated in the contexts of 
polyneuropathy, thus our results can be regarded as its validation in SFPN. Limitations of 
the current study include a relatively small number of participants for the ROC analysis, and 
bigger studies would more accurately define the diagnostic accuracy of COMPASS-31 in 
the context of SFPN. In addition, our assumption is that the patients’ SFPN is the underlying 
cause of their disautonomia, however, we cannot exclude concomitant central causes such as 
neurodegenerative disorders. Fortunately these are extremely rare in cohorts of this age.
In summary, we report good psychometric properties for COMPASS-31 and it is valid to use 
in SFPN patients. Most patients with SFPN remain undiagnosed, and the current findings 
suggest that the COMPASS-31 should be further evaluated as a first, easy-to-use, and 
inexpensive screening tool for SFPN.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Receiver operating characteristic plot of SFPN diagnosis performance by COMPASS-31
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Table 1
COMPASS-31 scores and Cronbach α values of the entire group (n=66)
COMPASS 31 Mean±Std Median Interquartile range Range Cronbach α
Total score 30.2±23.2 30.2 9.55-42.3 0-95.8 0.919
Orthostatic intolerance 14±12.4 16 0-24 0-36 0.898
Vasomotor 1.6±2.1 0 0-4.17 0-5 0.869
Secretomotor 5.4±6.9 3.21 0-8.57 0-34.3 0.246
Gastrointestinal 6.6±5.4 5.36 1.79-9.82 0-24.1 0.885
Bladder 1±1.6 0 0-1.11 0-6.7 0.598
Pupillomotor 1.7±1.4 1.67 0-2.75 0-4.3 0.910
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Table 2
Result of objective autonomic function testing as measured by the AFT and scored by the CASS (n=66)
AFT domains (CASS) Mean±Std Median Interquartile range Range
Total score 2.6±2.2 3 0-4 0-7
Cardiovagal 0.2±0.5 0 0-0 0-2
Adrenergic 1.2±1.4 0 0-3 0-4
Sudomotor 1.2±1.5 0 0-3 0-4
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Table 3
Correlation between COMPASS-31 and results of objective AFT as scored by CASS (n=66)
COMPASS 31 Autonomic function testing (CASS score)
Total score Cardiovagal Adrenergic Sudomotor
Total score 0.474* −0.103 0.148 0.608*
Orthostatic intolerance 0.433* −0.101 0.150 0.558*
Vasomotor 0.379* −0.024 0.040 0.551*
Secretomotor 0.327 −0.051 0.096 0.392*
Gastrointestinal 0.353 −0.020 0.050 0.476*
Bladder 0.172 −0.073 −0.063 0.350
Pupillomotor 0.246 −0.238 −0.001 0.465*
Spearman's correlations results. P values below 0.0017 are considered significant and marked with * based on Bonferroni corrections for 28 
comparisons.
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Table 4
Correlations between COMPASS-31 and measurements of pain and quality of life (n=66)
SF-MPQ-2 COMPASS-31 total score
        Total score 0.815*
    Continues pain 0.784*
    Intermittent pain 0.719*
    Neuropathic pain 0.737*
    Affective descriptors 0.743*
SF-36
        Total score −0.754*
    PCS −0.734*
    MSC −0.744*
NPS 0.622*
P values below 0.0055 are considered significant and marked with * based on Bonferroni corrections for 9 comparisons. SF-MPQ-2- The short-
form McGill pain questionnaire; SF-36- Short Form Health Survey; NPS- Numeric pain scale.
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Table 5
Differences in study measures between participants s with and without skin-biopsy diagnosis of SFPN (n=66)
ENF density < 5% (SFPN) ENF density > 5% (not SFPN)
COMPASS 31 Median (N=28) Median (N=38) U Z P value
        Total score 38.8 19.6 278 −3.296 0.001*
    Orthostatic intolerance 22.0 6.0 265.5 −3.571 <0.001*
    Vasomotor 1.7 0.0 395.5 −2.041 0.041
    Secretomotor 6.4 2.1 378.5 −2.048 0.041
    Gastrointestinal 7.1 5.4 408 −1.613 0.107
    Bladder 1.1 0.0 399 −1.93 0.054
    Pupillomotor 2.2 1.0 329 −2.662 0.008
SF-36
        Total score 33.1 77.9 205.5 −3.997 <0.001*
    Physical health 27.5 82.2 184 −4.291 <0.001*
    Mental Health 44.5 79.3 217 −3.840 <0.001*
SF-McGill-2
        Total score 3.7 0.5 216 −4.104 <0.001*
    Continuous pain 4.0 0.7 225 −3.994 <0.001*
    Intermittent pain 2.7 0.0 270.5 −3.468 0.001*
    Neuropathic pain 3.2 0.5 255.5 −3.610 <0.001*
    Affective descriptors 3.0 0.0 137 −3.773 <0.001*
Pain score (NPS) 6.0 1.0 238.5 −3.443 0.001*
Autonomic Function Testing (CASS)
        Total score 3 1.5 378.5 −2.031 0.046
    Cardiovagal 0 0 475 −0.843 0.399
    Adrenergic 0 0 487.5 −0.382 0.703
    Sudomotor 2 0 351.5 −2.320 0.020
P values below 0.0025 are considered significant and marked with * (Bonferroni corrections for 20 comparisons). SF-MPQ-2- The short-form 
McGill pain questionnaire; SF-36- Short Form Health Survey; NPS- Numeric pain scale.
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